Removal of poliovirus type 1 from a protein mixture using an immunoaffinity chromatography column

Biomedical Chromatography

Volumn 15, Issue 7, 2001, Pages 471-483

  Cameron Smith, Rachel ^a,b   Harbour, Colin ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AFFINITY CHROMATOGRAPHY; ANTIGEN-ANTIBODY REACTIONS; COLUMN CHROMATOGRAPHY;

CHROMATOGRAPHY COLUMNS; HUMAN PLASMAS; IMMUNOAFFINITY CHROMATOGRAPHY; IMMUNOAFFINITY MATRIX; POLIO VIRUS; POLYCLONAL; PROTEIN MIXTURES; REMOVAL METHOD; SEPHAROSE 4B; SUPERNATANTS;

VIRUSES;

ALBUMIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; POLYCLONAL ANTIBODY; SEPHAROSE;

ARTICLE; CONTROLLED STUDY; DRUG INDUSTRY; HUMAN; IMMUNOAFFINITY CHROMATOGRAPHY; NONHUMAN; PLASMA; POLIOMYELITIS VIRUS 1; PROTEIN ANALYSIS; SUPERNATANT;

HUMAN POLIOVIRUS 1;

EID: 0035170337     PISSN: 02693879     EISSN: None     Source Type: Journal    
DOI: 10.1002/bmc.98     Document Type: Article

References (47)

1. Purification by exploitation of activity-design and preparation of affinity adsorbents
2. Human antibody immunosorption of hepatitis B surface antigen from blood and plasma
3. Immunoaffinity chromatography
4. Chemical coupling of peptides and proteins to polysaccharides by means of cyanogen bromide
5. Relationship between nature and source of risk and process validation
6. Virus inactivation by addition of neutralizing antibodies
7. Chromatography in plasma fractionation: Benefits and future trends
8. The removal of model viruses, poliovirus type I and canine parvovirus, during the purification of human albumin using ion-exchange chromatographic procedures
9. Viral contamination of human plasma and procedures for preventing virus transmission by plasma products
10. Considerations in performing virus spiking experiments and process validation studies
11. Improved large-scale purification procedure of natural human fibroblast interferon
12. Active respiratory syncytial virus purified by ion-exchange chromatography: Characterization of binding and elution requirements
13. Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees
14. Viral aggregation: Buffer effects in the aggregation of poliovirus and reovirus at low and high pH
15. A third form of the G protein beta subunit. Purification and biochemical properties
16. Immunoaffinity purification and neutralization of scrapie prion infectivity
17. Purification by exploitation of activity-immunopurification
18. Studies on the use of sepharose-N-(6-aminohexanoyl)-2-amino-2-deoxy-D-glucopyranose for the large-scale purification of hepatic glucokinase
19. Hepatitis A. and B virus markers in immune serum globulin
20. Human fibroblast interferon, an improved purification
21. Affinity chromatography to remove viruses during preparation of plasma derivatives
22. Immunoaffinity purification of factor IX (Christmas factor) by using conformation-specific antibodies directed against the factor IX-metal complex
23. An introduction to affinity chromatography
24. Human hepatitis B vaccine from recombinant yeast
25. Chromatography and affinity separations
26. Note for guidance on virus validation studies: The design, contribution and interpretation of studies validating the inactivation and removal of viruses
27. Large-scale purification of human fibroblast interferon
28. Hepatitis B virus contains pre-S gene encoded domains
29. Affinity chromatography: Large-scale purification of the soluble oestradiol-17-dehydrogenase of human placenta
30. Purification of measles virus by affinity chromatography and by ultracentrifugation: A comparative study
31. Elimination of bacteriophages from tissue culture serum by affinity chromatography
32. Large-scale production and properties of immunoaffinity-purified human activated protein C concentrate
33. Immunity in hepatitis C infection
34. Immunoadsorbents
35. Factors affecting scale-up of affinity chromatography of β-galactosidase
36. Comparative sequence analysis of duck and human hepatitis B virus genomes
37. Purification and characterization of recombinant human leukocyte interferon with monoclonal antibodies
38. Formation and dissociation of virus-antibody complexes with special reference to the neutralization process
39. Removal of hepatitis B infectivity from factor-IX complex by hepatitis B immune-globulin
40. Development of an immunoaffinity process for Factor IX purification
41. Affinity Chromatography
42. Isolation of rat transferrin using CNBr-activated Sepharose 4B
43. Immunoaffinity purification of Factor VIII
44. Live attenuated influenza vaccines
45. Follow-up studies of hepatitis C association with an intravenous immunoglobulin